DTIL Stock Analysis: Buy, Sell, or Hold?
DTIL - Precision BioSciences, Inc. Common Stock
$6.92
-0.35 (-4.85%)
▼
5d:
-11.99%
30d:
-12.22%
90d:
+73.36%
WAIT
LOW Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 05, 2026
0d
Get Alerted When DTIL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: DTIL is down 12.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: DTIL is down 12.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: DTIL is currently trading at $6.92, which is considered oversold relative to its 30-day fair value range of $7.00 to $7.86.
Technical Outlook: Technically, DTIL is in a strong uptrend. Immediate support is located at $6.50, while resistance sits at $8.59. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $32.00 (+340.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DTIL is in a strong uptrend. Immediate support is located at $6.50, while resistance sits at $8.59. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $32.00 (+340.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.00 -
$7.86
Company Quality Score
56/100
(HOLD)
Options IV Signal
7th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
82.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 7th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.9%)
- BULLISH: Trading 340.2% below Wall St target ($32.00)
- WARNING: Recommendation downgraded due to -12.0% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$7.00 -
$7.86
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.23
(17.8%)
Support & Resistance Levels
Support Level
$6.50
Resistance Level
$8.59
Current Trend
Strong Uptrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.80
Wall Street Target
$32.00
(+340.2%)
Revenue Growth (YoY)
5261.1%
Profit Margin
-133.4%
Share & Embed Analysis
Last updated: May 18, 2026 3:37 PM ET
Data refreshes hourly during market hours. Next update: 4:37 PM
Data refreshes hourly during market hours. Next update: 4:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DTIL showing a specific setup today?
Insider Activity (6 Months)
3
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
J. Jefferson Smith
SELL
4925 shares
2026-02-18
John Alexander Kelly
SELL
8149 shares
2026-02-18
Michael Amoroso
SELL
20559 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 56 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 51 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 56 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$203 | 53 HOLD |
